$2.5M NIH Award to Develop a Multi-Modal Remote Monitoring Solution for FTLD Syndromes

BioSensics is pleased to announce a $2.5M/2-year award from the U.S. National Institute of Health (NIH) to develop a robust multi-modal solution for remote monitoring of motor, speech, and cognitive function in Frontotemporal lobar degeneration (FTLD) syndromes. FTLD syndromes span the spectrum of neurodegenerative disorders affecting movement and cognitive function and are pathologically related to Alzheimer’s disease.

The remote monitoring solution includes 1) a PAMSys sensor for at-home monitoring of physical activity, posture, falls, and function, and 2) BioDigit Home for digital speech, psychomotor, and cognitive assessments related to tracking FTLD syndromes.

The award is in collaboration with Dr. Anne-Marie Wills, MD, Director of the CurePSP Center of Care at Massachusetts General Hospital, and Dr. Alex Pantelyat, MD, Director, Atypical Parkinsonism Center at the Johns Hopkins School of Medicine. We will initially recruit 60 participants with progressive supranuclear palsy (PSP, a rapidly progressing FTLD syndrome), who will be monitored for 12 months. The project will later be extended to corticobasal syndrome and frontotemporal dementia.

There are currently more than 130 ongoing clinical trials in FTLD syndromes, including approximately 20 trials in PSP. Our solution has the immediate potential to positively impact PSP and other FTLD syndrome clinical trials by improving the way disease severity and progression are measured.

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now being used by thousands of older adults.

BioSensics is the only company that develops and provides end-to-end solutions and services for the collection of digital measures and biomarkers in clinical trials and research. All components of BioSensics solutions, including the wearable sensors, software, and algorithms are developed and validated by BioSensics. The U.S. National Institute of Health (NIH) has awarded BioSensics over $50M to support its research and development programs. In 2022, NIH selected BioSensics to develop remote measurement technologies for use in clinical trials in individuals with rare diseases.